BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 119 filers reported holding BIOXCEL THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.54 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $28,872 | -64.7% | 11,412 | -7.0% | 0.00% | – |
| Q2 2023 | $81,685 | -63.8% | 12,265 | +1.3% | 0.00% | -100.0% |
| Q1 2023 | $225,842 | -6.0% | 12,103 | +8.2% | 0.00% | 0.0% |
| Q4 2022 | $240,189 | +172.9% | 11,182 | +50.0% | 0.00% | 0.0% |
| Q3 2022 | $88,000 | -15.4% | 7,456 | -5.0% | 0.00% | 0.0% |
| Q2 2022 | $104,000 | -39.5% | 7,851 | -4.3% | 0.00% | 0.0% |
| Q1 2022 | $172,000 | +0.6% | 8,204 | -2.7% | 0.00% | 0.0% |
| Q4 2021 | $171,000 | -32.7% | 8,435 | +0.7% | 0.00% | 0.0% |
| Q3 2021 | $254,000 | +66.0% | 8,380 | +58.7% | 0.00% | 0.0% |
| Q2 2021 | $153,000 | -30.1% | 5,280 | +3.9% | 0.00% | 0.0% |
| Q1 2021 | $219,000 | +157.6% | 5,083 | +176.9% | 0.00% | 0.0% |
| Q4 2020 | $85,000 | +6.2% | 1,836 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $80,000 | – | 1,836 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Logos Global Management LP | 430,000 | $19,866,000 | 1.70% |
| APIS CAPITAL ADVISORS, LLC | 20,000 | $924,000 | 0.89% |
| Avidity Partners Management LP | 547,000 | $25,271,000 | 0.82% |
| Knoll Capital Management, LLC | 20,000 | $924,000 | 0.63% |
| Artemis Investment Management LLP | 1,013,448 | $46,839,000 | 0.49% |
| AlphaCentric Advisors LLC | 25,000 | $1,155,000 | 0.48% |
| First Light Asset Management, LLC | 94,202 | $4,352,000 | 0.32% |
| Ikarian Capital, LLC | 150,000 | $6,930,000 | 0.31% |
| Longitude (Cayman) Ltd. | 8,000 | $370,000 | 0.18% |
| AllSquare Wealth Management LLC | 5,490 | $254,000 | 0.17% |